DDInter255 DDInter1561
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first approved by the FDA in May 2013 and is currently marketed under the brand name Xofigo, which was formerly called Alpharadin. Xofigo is indicated in patients who have metastatic bone cancer that is symptomatic with no visceral metastases and patients who have prostate cancer that is castration resistant. The FDA label includes a warning that Radium Ra 223 Dichloride should not be used in women who are pregnant or may become pregnant due to the high risk of fetal harm.
Busulfan {u} (Compound) causes {v} (Side Effect) Extravasation
Extravasation {u} (Side Effect) is caused by {v} (Compound) Radium Ra 223 dichloride
Busulfan {u} (Compound) causes {v} (Side Effect) Extravasation
Extravasation {u} (Side Effect) is caused by {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Radium Ra 223 dichloride
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Lomustine
Lomustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Radium Ra 223 dichloride
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Lomustine
Lomustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Radium Ra 223 dichloride
Busulfan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Alkylating Activity {u} (Pharmacologic Class) includes {v} (Compound) Lomustine
Lomustine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Radium Ra 223 dichloride
Busulfan {u} (Compound) downregulates {v} (Gene) RALA
RALA {u} (Gene) is upregulated by {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Radium Ra 223 dichloride
Busulfan {u} (Compound) downregulates {v} (Gene) RALA
RALA {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Radium Ra 223 dichloride
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Abiraterone
Abiraterone {u} may lead to a major life threatening interaction when taken with {v} Radium Ra 223 dichloride
Busulfan {u} (Compound) upregulates {v} (Gene) TP53BP2
TP53BP2 {u} (Gene) is upregulated by {v} (Compound) Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Radium Ra 223 dichloride
Busulfan {u} (Compound) upregulates {v} (Gene) TP53BP2
TP53BP2 {u} (Gene) is downregulated by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Radium Ra 223 dichloride
Busulfan (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Busulfan (Compound) causes Extravasation (Side Effect) and Extravasation (Side Effect) is caused by Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Lomustine (Compound) and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomustine (Compound) and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Busulfan (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Lomustine (Compound) and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Busulfan (Compound) downregulates RALA (Gene) and RALA (Gene) is upregulated by Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Busulfan (Compound) downregulates RALA (Gene) and RALA (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Abiraterone (Compound) and Abiraterone may lead to a major life threatening interaction when taken with Radium Ra 223 dichloride
Busulfan (Compound) upregulates TP53BP2 (Gene) and TP53BP2 (Gene) is upregulated by Vinorelbine (Compound) and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride
Busulfan (Compound) upregulates TP53BP2 (Gene) and TP53BP2 (Gene) is downregulated by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Radium Ra 223 dichloride